Simulations Plus, a leading provider of advanced modeling and simulation software for drug discovery and development, has announced the establishment…
Read More
From List Price to Net Price: How Finance Leaders Decode Real Drug Costs
In the intricate landscape of the healthcare industry, the discourse surrounding drug pricing frequently fixates on the list price. Public…
Read More
How digital tools and AI are accelerating drug discovery
The pharmaceutical industry stands at a critical juncture, grappling with escalating costs and protracted timelines in the arduous journey of…
Read More
Corcept’s first-in-class ovarian cancer drug gains FDA approval – Pharmaceutical Technology
Corcept Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its selective…
Read More
The US Food and Drug Administration Convenes Public Hearing Amidst Scrutiny of Commissioner’s National Priority Voucher Program
The US Food and Drug Administration (FDA) is set to convene a significant public hearing on June 12, 2026, a…
Read More
Breakthrough in Quinine Biosynthesis Unlocks Sustainable Drug Production from Cinchona Tree Enzymes
A century-long scientific enigma has been resolved by a collaborative research team, revealing the intricate enzymatic machinery within the Cinchona…
Read More
Plastic waste transformed into Parkinson’s drug in bioengineering first
A groundbreaking innovation emerging from The University of Edinburgh in the United Kingdom has unveiled a novel technology capable of…
Read More
DenovAI’s physics-based bet on one-shot drug design
Rethinking the Drug Discovery Paradigm For decades, the pharmaceutical industry has operated on a well-established, albeit arduous, pipeline: identify "hit"…
Read More
TrumpRx.gov: A Federal Portal Faces Scrutiny Amidst Concerns Over Direct-to-Consumer Drug Sales and Patient Safety.
As of early February, the federal portal TrumpRx.gov remains in a nascent state, displaying only a stylized Oval Office portrait…
Read More
The ‘forever drug’ assumption about GLP-1s may be wrong, according to nference analysis
A groundbreaking shift in the understanding of weight management outcomes following the cessation of GLP-1 agonist medications is emerging, challenging…
Read More
